Kezar Life Sciences reposted this
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be applied across a vast array of indications to create victories for patients most in need.
External link for Kezar Life Sciences
4000 Shoreline Ct
Suite 300
South San Francisco, California 94080, US
Kezar Life Sciences reposted this
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
Today, we released our second quarter 2024 financial results along with recent business updates. Learn more in the full news release here: https://lnkd.in/g27h6C9h
We are excited to share that our partner, Everest Medicines, has dosed the first patient in China. Their team continues to integrate seamlessly with ours to drive forward our global Phase 2b clinical trial evaluating zetomipzomib in adults living with LN. https://lnkd.in/gJu83GfZ
Zetomipzomib is the only selective immunoproteasome inhibitor being evaluated in clinical trials for lupus nephritis. Learn more about the PALIZADE trial at https://lnkd.in/gtxDfybE. #PALIZADEtrial #zetomipzomib #LupusNephritis
Kezar Life Sciences reposted this
Section Chief of Hepatology/Associate Director of Organ Transplantation at Rush University Medical Center
Let’s aim for a steroid-free future to treat #autoimmunehepatitis! Read about treatments in development for #AIH in @HepCommJournal [https://lnkd.in/gGd4QDFX]. #openacess https://lnkd.in/gjnJ8wEy
Tomorrow, Kezar’s CEO Chris Kirk will participate in a fireside chat at the Jefferies Global Healthcare Conference! A webcast of the discussion will be available on our website's “Events & Presentations” section here: https://lnkd.in/eQbXMpBN. #Jefferies #Healthcare #LupusNephritis
Lupus nephritis is a frequent and moderate-to-severe complication of lupus affecting the kidneys. Learn about Kezar’s selective immunoproteasome inhibitor zetomipzomib being evaluated for those living with lupus nephritis: https://lnkd.in/gtxDfybE. #LupusAwarenessMonth
Today, we announced our participation in the Jefferies Global Healthcare Conference in #NewYorkCity next week. Learn more about our upcoming fireside chat in our latest press release here: https://lnkd.in/gZn2_Gdu #Jefferies #Healthcare #Zetomipzomib
Letzte Runde
Eigenkapital nach dem IPOUS$ 12.2M
Investoren